Varenicline for Smoking Cessation in Hospitalized Patients With Psychiatric Disorders

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2019

Primary Completion Date

April 30, 2020

Study Completion Date

April 30, 2020

Conditions
Tobacco Use CessationPsychiatric Disorders
Interventions
DRUG

Varenicline

All participants randomized to varenicline will be titrated to the full dose during the first week and continued up to week 12 following standard dosage. This would be independent of time of discharge, so patients will continue the same treatment after discharge up to complete the 12 weeks.

DRUG

Nicotine patch

Patients randomized to nicotine patch will receive 8 weeks of 21mg patch followed by 2 weeks of 14 mg patch and 2 weeks of 7 mg patch.

Trial Locations (4)

08017

Galatea Clinic, Barcelona

08035

Sant Rafael Hospital, Barcelona

Vall d'Hebron Institute of Research, Barcelona

08041

Hospital de Sant Pau, Barcelona

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Clínica Galatea

UNKNOWN

collaborator

Hospital Sant Rafael

UNKNOWN

collaborator

Hospital de Sant Pau

OTHER

lead

Hospital Universitari Vall d'Hebron Research Institute

OTHER

NCT03809897 - Varenicline for Smoking Cessation in Hospitalized Patients With Psychiatric Disorders | Biotech Hunter | Biotech Hunter